Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd has announced the first commercial sales of its geneType™ products following the acquisition of Genetype in December 2024. The company anticipates significant sales growth driven by enterprise market focus, geographic expansion, and support from key opinion leaders. The geneType™ platform offers comprehensive risk assessments for various diseases, positioning Rhythm well in the preventative healthcare market. The company also plans to expand revenues with ColoSTAT® sales in the next financial year, further strengthening its market position.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Established in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden. Rhythm collaborates with global partners to commercialize and distribute its diagnostic solutions, including the ColoSTAT® Test-Kit for colorectal cancer and the geneType™ platform for genetic risk assessment across multiple diseases.
YTD Price Performance: -5.56%
Average Trading Volume: 333,176
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$24.37M
For an in-depth examination of RHY stock, go to TipRanks’ Stock Analysis page.